GBA Presents: House of Gummy-!

I don't know if we are going to grab a quick $10-$15 on TEAM and sell at $220 or really
commit.

Extremely abbreviated morning as i pack up and head back to Ct! I am crazy in the head now with the sudden realization my summer ends Fri.-

Gots to get a few more swims in. Got to get the boiler going it was 48 this morning//
 
BUY IDEA #1--> PINTRUST WE TALKED ABOUT PINS LAST NIGHT. I DON'T THINK WE'LL GET MUCH MORE THAN $3 OR $4 UPSIDE BUT WHY NOT?

BUY IDEA #2--> Tidewater This is the most powerful oil name.

-Tidewater price target raised to $91 from $75 at BTIG » 07:15 TDW
 
BUY IDEA #3--> ADD TO HELIX

WE ALREADY OWN THIS GREAT NAME FROM RADIO GUMMY OUR LAST SUPERSTAR STOCK PICKING THREAD.. $7-----$10 :wtf: BUT I THINK WE CAN GET MORE. A LOT MORE.
#12->Helix Energy Solutions Group, Inc. (HLX)
NYSE - NYSE Delayed Price.
6.84+0.09 (+1.33%)

Helix Energy price target raised to $17 from $14 at BTIG » 07:15 HLX :strong:
 
--ClearSign receives new funding for its Hydrogen Ultra Low NOx burner project » 07:13 CLIR

--Pinterest price target raised to $38 from $35 at Rosenblatt » 07:07 PINS

--Amazon seasonal hiring plans 'a bullish leading indicator,' says Morgan Stanley » 06:54 AMZN

--Wingstop upgraded to Outperform from Neutral at Wedbush » 06:39 WING

--Red Cat subsidiary signs $1.8M contract with U.S. CBP » 06:28 RCAT
 
TODAY'S 2ND GUMMY- PL

Planet Labs PBC (PL)
NYSE - NYSE Delayed Price.

2.7000+0.0100 (+0.37%)
At close: September 19 04:00PM EDT
2.8400 +0.14 (+5.19%)<-------------------
Pre-Market: 07:22AM EDT



Insider Buying: Co-Founder and CEO William Marshall Acquires 100,000 Shares of Planet Labs PBC (PL)
 
WHAT HAPPENED:

Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke


Licensing
  • 04:18 PM ET 09/19/2023


Revance Therapeutics (RVNC) is reversing course to stay competitive with AbbVie's (ABBV) market-leading aesthetics drug, Botox — and RVNC stock crashed Tuesday in response.

The company said earlier this year it was going after "prestige" accounts with its Daxxify, the newest in a class of botulinum toxins that smooth frown lines. But, during an investor day update, Revance said it's cutting Daxxify prices "to be priced competitively with Botox" and "accelerate market share expansion."

The news is likely to put a damper on analysts' expectation for $247.4 million in sales this year.

On today's stock market, RVNC stock crashed 17.3% to 13.81. Earlier, shares fell as much as 33.5%. Revance stock was among the worst-performing biotech stocks on Tuesday.

RVNC Stock: Competing With AbbVie
AbbVie is easily the market leader for botulinum toxin injections. It first gained approval in 2002. Now, Botox Cosmetic is a $2 billion-plus annual product. Sales are expected to top $3 billion in 2025 and $4 billion just three years later, according to FactSet.
 
PT $44 // PARTIALLY DE RISKED STK $13.50

Revance Therapeutics, Inc. (RVNC)
NasdaqGM - NasdaqGM Real Time Price.

13.81-2.89 (-17.31%)
At close: September 19 04:00PM EDT
13.48 -0.33 (-2.39%)<--------------------:rolleyes:
Pre-Market: 07:07AM EDT
 
You must log in or register to reply here.
Back
Top